Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL848471 | 1.00 | PKM (0.40) | PKMSMN1; SMN2ALDH1A1KMT2ANAMPT | |
| SCHEMBL849915 | 0.89 | TSHR (0.46) | PKMSMN1; SMN2ALDH1A1KMT2ANAMPT | |
| SCHEMBL849914 | 0.89 | TSHR (0.46) | PKMSMN1; SMN2ALDH1A1KMT2ANAMPT | |
| SCHEMBL849419 | 0.88 | PTH1R (0.37) | — | |
| SCHEMBL849418 | 0.88 | PTH1R (0.37) | — | |
| SCHEMBL13555080 | 0.85 | PTH1R (0.36) | KMT2AELANE | |
| SCHEMBL850753 | 0.85 | PTH1R (0.43) | PKMSMN1; SMN2ALDH1A1KMT2ANAMPT | |
| SCHEMBL850177 | 0.84 | PTH1R (0.38) | ALDH1A1ELANEGRIN1GRIN2B | |
| SCHEMBL850176 | 0.84 | PTH1R (0.38) | ALDH1A1ELANEGRIN1GRIN2B | |
| SCHEMBL849974 | 0.84 | PTGS2 (0.41) | KMT2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | claimed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | claimed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | claimed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | claimed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | claimed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PKM 598/4885SMN1; SMN2 1005/4885ALDH1A1 836/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PKM 598/4885SMN1; SMN2 1005/4885ALDH1A1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.